Firmagon

Firmagon is a brand name of degarelix, approved by the FDA in the following formulation(s):

FIRMAGON (degarelix acetate - powder; subcutaneous)

• 
  Manufacturer: FERRING
  
  Approval date: December 24, 2008
  
  Strength(s): EQ 120MG BASE/VIAL ^[RLD], EQ 80MG BASE/VIAL
  

Has a generic version of Firmagon been approved?

No. There is currently no therapeutically equivalent version of Firmagon available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Firmagon. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  GnRH antagonists
  Patent 5,925,730
  Issued: July 20, 1999
  Inventor(s): Semple; Graeme & Jiang; Guangcheng
  Assignee(s): Ferring BV
  Peptides are provided which have improved duration of GnRH antagonistic properties. These antagonists may be used to regulate fertility and to treat steroid-dependent tumors and for other short-term and long-term treatment indications. These antagonists have a derivative of aminoPhe or its equivalent in the 5- and/or 6-positions. This derivative contains a carbamoyl group or a heterocycle including a urea in its side chain. Particularly effective decapeptides, which continue to exhibit very substantial suppression of LH secretion at 96 hours following injection, have the formulae: Ac-D-2Nal-D-4Cpa-D-3Pal-Ser-4Aph(hydroorotyl)-D-4Aph(acetyl)-Leu-Lys(isopr opyl)-Pro-D-Ala-NH.sub.2, and Ac-D-2Nal-D-4Cpa-D-3Pal-Ser-4Aph(hydroorotyl)-D-4Amf(Q.sub.2)-Leu-Lys(isop ropyl)-Pro-D-Ala-NH.sub.2, wherein Q.sub.2 is Cbm or MeCbm.
  
  Patent expiration dates:
  
  
  • April 11, 2017
    
    ✓ 
    Patent use: GNRH ANTAGONIST INDICATED FOR TREATMENT OF PATIENTS WITH ADVANCED PROSTATE CANCER
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • December 24, 2013 - NEW CHEMICAL ENTITY
  
  

See also...

• Firmagon Consumer Information (Drugs.com)
• Firmagon Consumer Information (Cerner Multum)
• Degarelix Consumer Information (Drugs.com)
• Degarelix Acetate Consumer Information (Wolters Kluwer)
• Degarelix Consumer Information (Cerner Multum)
• Degarelix Subcutaneous Advanced Consumer Information (Micromedex)